Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26464795 | 0.88 | DGAT1 (0.33) | DGAT1AAK1RET | |
| SCHEMBL20190978 | 0.86 | CYP1A2 (0.41) | DGAT1AAK1CYP1A2 | |
| SCHEMBL20190868 | 0.84 | SCN5A (0.39) | SCN5ADGAT1AAK1FEN1CYP1A2 | |
| SCHEMBL20209044 | 0.83 | CYP1A2 (0.44) | SCN5ADGAT1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL26459650 | 0.79 | CYP1A2 (0.38) | DGAT1AAK1CYP1A2RET | |
| SCHEMBL20190924 | 0.77 | SCN5A (0.54) | SCN5ADGAT1AAK1FEN1CYP1A2 | |
| SCHEMBL26462639 | 0.76 | CYP1A2 (0.40) | SCN5ADGAT1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL22712656 | 0.76 | SCN5A (0.65) | SCN5ADGAT1CYP1A2 | |
| SCHEMBL26462340 | 0.76 | DGAT1 (0.35) | DGAT1AAK1 | |
| SCHEMBL12909263 | 0.73 | AR (0.40) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2018098491-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | SCN5A 7/4885DGAT1 464/4885AAK1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.